Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Variceal Ligation in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for endoscopic variceal ligation cohort~* All paediatric patients (\< 18 years)~* Known chronic liver disease~* Suspicion of portal hypertension based on splenomegaly in the ultrasound, presence of collaterals in the abdominal wall or low platelet count (\<150.000 platelets/L),~* Grade 2 or 3 esophageal varices or red spots, regardless of the grade of the esophageal varices diagnosed by endoscopy~* From January 2014 to April 2017~Exclusion Criteria for endoscopic variceal ligation cohort:~* Patients initially treated with Non-selective beta blockers and subsequently treated with endoscopic variceal ligation as primary prophylaxis were excluded of the study.~* Patients for whom endoscopic variceal ligation was not feasible because of patients' weight/seize were also excluded of the study.~Inclusion Criteria for propranolol cohort~* All paediatric patients (\< 18 years)~* Known chronic liver disease~* Suspicion of portal hypertension based on splenomegaly in the ultrasound, presence of collaterals in the abdominal wall or low platelet count (\<150.000 platelets/L),~* Grade 2 or 3 esophageal varices or red spots, regardless of the grade of the esophageal varices diagnosed by endoscopy~* That received propranolol as primary prophylaxis~* From January 2009 to December 2013.~Exclusion Criteria propranolol cohort:~* Patients initially treated with non-selective beta blockers and subsequently treated with endoscopic variceal ligation as primary prophylaxis were excluded of the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Endoscopic Variceal Ligation (Type: None): From January 2014 to April 2017, all paediatric patients with a known chronic liver disease with suspicion of portal hypertension who presented grade 2 or 3 esophageal varices or red spots in the upper endoscopy received primary prophylaxis with endoscopic variceal ligation.
- Propranolol Group (Type: None): Patients in the Endoscopic Variceal Ligation group were compared with an historical cohort of 30 consecutive patients with portal hypertension and grade 2 or 3 esophageal varices or red spots who received propranolol as primary prophylaxis from January 2009 to December 2013. All patients were treatment-naïve in regards of their upper gastrointestinal bleeding prophylaxis at the time of the first upper endoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).